Incyte (INCY) Earnings Date & Reports

Incyte delivered robust first quarter results, with total revenue of $1.27 billion, surpassing consensus estimates of $1.22 billion and reflecting 21% YoY growth. Total net product sales climbed 20% to $1.10 billion. Jakafi net sales were $758 million, up 7% YoY, supported by broad demand across indications. Opzelura, the company's ruxolitinib cream for atopic dermatitis and vitiligo, posted $143 million in sales, a 20% increase, with U.S. prescriptions up 17%.

The hematology and oncology portfolio excluding Jakafi surged 116% to $204 million, fueled by Niktimvo ($55 million), Monjuvi/Minjuvi ($49 million), and Zynyz ($41 million). Royalty revenues added $151 million, up 16%. Non-GAAP diluted EPS came in at $1.81, well ahead of expectations, while GAAP diluted EPS was $1.47. GAAP R&D expenses rose 18% to $516 million amid pipeline investments; SG&A (selling, general, and administrative) increased 1% to $328 million.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your investment strategy.

Market Reaction and Investor Sentiment

Despite beating top- and bottom-line estimates, Incyte's stock declined 0.75% to nearly 4% in post-earnings trading on April 28-29, 2026. Investors appeared to focus on the reaffirmed full-year guidance midpoint, perceived as below some heightened expectations, overshadowing the quarter's strong execution and pipeline updates. Sentiment remains cautiously optimistic, balancing near-term sales momentum with long-term diversification risks.

Forward Outlook and Key Factors to Monitor

Incyte reaffirmed its 2026 net sales guidance at $4.77-$4.94 billion, implying steady growth from core products. Jakafi is projected at $3.22-$3.27 billion, incorporating the mid-2026 launch of Jakafi XR, an extended-release formulation. Opzelura guidance of $750-$790 million factors in potential European approval for moderate atopic dermatitis in the second half. The hematology/oncology segment eyes $800-$880 million, driven by geographic expansions for Zynyz, Niktimvo, and others.

Pipeline catalysts loom large, with four approvals and launches expected from mid-2026 to early 2027, including povorcitinib for hidradenitis suppurativa (HS) and vitiligo. Positive Phase 3 data for povorcitinib in vitiligo supports filings in H1 2027; HS topline results are due Q4 2026. Hematology readouts include INCA033989 Phase 3 initiations mid-2026 and axatilimab data H2 2026. Oncology advances feature a new Phase 3 for INCB161734 in pancreatic cancer and Zynyz expansions.

Investors should track R&D expense trends ($3.205-$3.375 billion non-GAAP for 2026), gross margins amid launches, and commercial uptake for newer assets. Leadership changes, including new CFO Suketu Upadhyay effective May 2026, add stability. Broader biotech dynamics, like competition in JAK inhibitors and inflammation, will influence execution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations